Clinical stage biotechnology company aTyr Pharma, Inc. (NASDAQ:ATYR) is expected to be added to the Russell 2000 and Russell 3000 indexes, effective after market close on June 27, 2025, according to a company announcement.
The Russell 3000 Index tracks the performance of the 3,000 largest publicly traded U.S. companies and serves as a benchmark for the U.S. equity market. The Russell 2000 Index, a subset of the Russell 3000, specifically tracks small-cap companies.
Membership in these indexes lasts for one year and includes automatic inclusion in appropriate growth and value style indexes. Investment managers and institutional investors commonly use Russell Indexes for index funds and as benchmarks for active investment strategies.
aTyr Pharma focuses on developing treatments derived from tRNA synthetase biology. The company’s lead therapeutic candidate, efzofitimod, is a biologic immunomodulator in clinical development for treating interstitial lung disease, which encompasses immune-mediated disorders that can cause inflammation and progressive fibrosis of the lungs.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.